Hypertension is a common disease in our

Size: px
Start display at page:

Download "Hypertension is a common disease in our"

Transcription

1 AJH 2000;13: Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population. Nonsteroidal anti-inflammatory drugs are often used to relieve pain in arthritic patients but a side effect is sodium retention and consequent elevation of blood pressure (BP). The effect of dihydropyridine calcium blocking drugs is relatively independent of sodium intake, whereas the angiotensin-converting enzyme (ACE) inhibitors effects can be blunted by a high-sodium diet. This study compared the effects of indomethacin with placebo in elderly patients with essential hypertension who had been controlled with amlodipine or enalapril. Indomethacin 50 mg twice daily or placebo was administered for 3 weeks in a double-blind crossover study to patients controlled with amlodipine or enalapril. The response was assessed by ambulatory BP measurement. Indomethacin raised BP and lowered pulse rates in patients taking enalapril but had little effect in patients receiving amlodipine. The difference caused by indomethacin between the two groups was 10.1/4.9 mm Hg increase in BP and a 5.6 beats/min fall in pulse in people taking enalapril. Addition of indomethacin to patients taking either drug caused a rise in weight and a fall in plasma renin. It is postulated that the effect is due to inhibition of prostaglandin synthesis, which causes sodium retention. In patients taking amlodipine, the fall in plasma renin ameliorates the effect of sodium retention on BP. In patients taking enalapril, plasma renin falls but this is not translated into an effect because of the blockage of converting enzyme. Thus, the full effect of sodium retention on BP is expressed. In patients treated with indomethacin, fewer patients may respond to ACE inhibitors. However, the major problem is the patient who intermittently takes indomethacin or other nonsteroidal anti-inflammatory drugs, which, if a person is treated by an ACE inhibitor causes BP to go out of control. In such patients amlodipine would appear to be a preferred choice to enalapril. Am J Hypertens 2000;13: American Journal of Hypertension, Ltd. KEY WORDS:, enalapril, calcium blocking drugs, ACE inhibitors, indomethacin, nonsteroidal anti-inflammatory drugs, arthritis, hypertension, blood pressure. Hypertension is a common disease in our community and the prevalence increases as the population ages. In elderly people arthritis and other inflammatory problems become more frequent and a significant number of people are treated with nonsteroidal anti-inflammatory drugs (NSAID). NSAID cause salt and water retention and this may be the reason they elevate blood pressure (BP) in both normotensive and hypertensive people. 1 3 If a person is taking an NSAID and is being Received November 12, Accepted April 4, From the Department of Physiology, University of Melbourne and Hypertension Clinic, ARMC, Heidelberg, Australia. This study was supported by Pfizer Pty. Limited. Address correspondence and reprint requests to Prof. T. Morgan, Department of Physiology, University of Melbourne, Parkville, Victoria 3052, Australia; t.morgan@physiology.unimelb.edu.au 2000 by the American Journal of Hypertension, Ltd /00/$20.00 Published by Elsevier Science, Inc. PII S (00)

2 1162 MORGAN ET AL AJH NOVEMBER 2000 VOL. 13, NO. 11 treated for hypertension the dose of the drug will be increased or the drug altered so that the hypertension is controlled. However, if a person intermittently takes a NSAID the BP may be controlled when they are not taking the NSAID and go out of control when NSAID is used. People taking a NSAID may not respond to certain antihypertensive drug classes as well as to others. When therapy is started with most classes of antihypertensive drugs, some sodium retention may develop because of BP reduction. This may lead to a person becoming relatively insensitive to the drug and the addition of a diuretic frequently allows control to be maintained. The response to the angiotensin-converting enzyme (ACE) inhibitors is relatively sensitive to the sodium intake of an individual. 4 The lower the sodium intake, the greater the fall in BP when an ACE inhibitor is used. This probably relates to the compensatory rise in renin and hence angiotensin II that occurs when sodium restriction is introduced. 5,6 This in turn blunts the response to sodium restriction and then blockade of this system causes a fall in BP. With the calcium-channel blocking drugs the response appears to be independent of sodium chloride intake and in this regard they differ from most other antihypertensive drugs. 7 In addition, diuretics appear to have little additional effect when a person is taking a calcium-channel blocking drug. 8,9 In view of the fairly extensive association of arthritis and hypertension, this study was undertaken to see if people responded in a different way when a NSAID was used according to the class of drug they were taking. The two classes of drugs that were studied were an ACE inhibitor (enalapril) and a dihydropyridine calcium-channel blocking drug (amlodipine). The NSAID used was indomethacin, as this compound has clearly shown elevations in BP with its administration. 3,10 METHODS The patients recruited to the study were men and women, age 45 to 85 years, with essential hypertension well controlled taking either 20 or 40 mg/day enalapril or 5 or 10 mg/day amlodipine. This control was assessed by BP measured 24 h after drug administration. The patients entered a preliminary 2-week run-in period during which they received twice-daily placebo matching indomethacin. They continued taking their normal dose of enalapril or amlodipine. The enalapril or amlodipine was taken between 6:00 am and 9:00 am. On the day of their visit to the clinic they did not take their antihypertensive medication. Supine BP was recorded at the time of entry and at Week 2 of the run-in period. The BP was required to be lower than 160/90 mm Hg and the supine diastolic BP should not have differed by 5 mm Hg between the two consecutive visits. People who met these criteria were then randomized to the study. The study consisted of two parallel groups, one receiving enalapril and the other receiving amlodipine. Patients who met the entry criteria were randomized to a double-blind crossover study in which they received placebo, 1 capsule twice daily, or indomethacin, 50 mg twice daily. Each study period was 3 weeks in duration. Each patient was seen at Week 2 and Week 3 of each study period. At Week 3 of the study the patient had an ambulatory BP monitor fitted, was given study medication, and was seen the following day. The ambulatory BP monitoring continued for 26 to 27 h in most patients. The following patients were excluded from the study: patients with evidence of a cardiovascular or cerebrovascular episode within the previous 6 months or with unstable angina; patients in cardiac failure or heart block; patients with a history of peptic ulceration or gastrointestinal bleeding; patients with renal or hepatic dysfunction. Patients were not allowed to be receiving other antihypertensive drugs or NSAID. However, a dose of aspirin up to 650 mg daily was permitted. Informed consent was received from each patient and the study was approved by the Ethics Committee of the Austin & Repatriation Medical Centre. At each visit the patients were weighed, the BP was recorded in triplicate after 10 min supine and 5 min erect; a mean value was recorded for each. Blood was taken at the end of the run-in and at the end of each treatment period. Routine biochemistry was performed on this blood, but in addition, plasma renin and aldosterone were measured. The ambulatory BP was performed over a 26- to 27-h period using A&D model TM Blood pressure was taken every 15 min day and night and standard exclusion criteria were applied to the BP. The ambulatory BP was divided into the 24-h mean, the daytime mean, the nighttime mean, and the morning mean. The daytime mean was taken as the interval between 6:00 am and 10:00 pm, the nighttime mean as the BP between 10:00 pm and 6:00 am, and the morning mean as the 2-h period starting after the patient got out of bed. Power calculations indicated that to detect a 5-mm Hg difference in supine systolic BP between patients taking indomethacin or placebo, assuming a standard deviation of 8 mm Hg and a power of 80% required a total of 44 patients, 22 taking amlodipine and 22 taking enalapril. The prime response analyzed was the change in 24-h ambulatory BP after the addition of indomethacin to treatment with amlodipine compared to the change after its addition to treatment with enalapril. In addition to this primary analysis, changes in the daytime mean, the nighttime mean, and the morning mean of

3 AJH NOVEMBER 2000 VOL. 13, NO. 11 INDOMETHACIN AND HYPERTENSION 1163 TABLE 1. FLOW PATTERN* Entered run-in Randomized Withdrawn Adverse events 3 4 Patient s request 3 1 Completed placebo and indomethacin Two satisfactory ABPM Protocol violation 0 1 Clinic analysis ABPM analysis ABPM ambulatory blood pressure monitoring. * Primary analysis, change in 24-h mean blood pressure caused by indomethacin in patients taking enalapril or amlodipine. TABLE 2. DEMOGRAPHICS OF PATIENTS WHO COMPLETED THE PROTOCOL AND HAD SATISFACTORY ABPM TAKING PLACEBO AND INDOMETHACIN Group Group Age; mean range (yr) 72; ; Gender (M/F) 15/3 18/5 Weight (kg) Height (cm) Years of hypertension Systolic blood pressure (mm Hg) Diastolic blood pressure (mm Hg) Pulse (beats/min) Abbreviation as in Table 1. the ambulatory BP were analyzed. Secondarily, the effect inside the two groups of placebo compared to indomethacin was assessed by the null hypothesis. RESULTS Sixty-five patients entered the run-in phase of the study; 30 of 33 patients taking enalapril and 31 of the 32 patients taking amlodipine were randomized to placebo or indomethacin. Three patients in both the enalapril and amlodipine group withdrew because of side effects and three people taking enalapril and one taking amlodipine were withdrawn at their request. Twenty-four of the patients taking enalapril completed both phases of the study but only 18 of these had a satisfactory ambulatory BP monitor on two occasions. Twenty-six patients receiving amlodipine completed the study and 24 of these had satisfactory ambulatory BP monitors on both occasions. The main reason for unsatisfactory ambulatory BP recordings was failure to meet standard preset requirements. One patient in the amlodipine group had a protocol violation by receiving prednisolone during the study and was accordingly excluded from the analysis (Table 1). The analysis based on clinic values was accordingly done on 24 patients taking enalapril and 25 taking amlodipine. The ambulatory BP analysis (the primary analysis) was done in 18 patients taking enalapril and 23 taking amlodipine. In a double-blind crossover study without values determined at the end of a run-in phase it is only possible to do the analysis on people who complete both arms. The demographics of these patients are shown in Table 2 and it can be seen that the patient groups were similar. Two patients were slightly outside the age entry criteria but were included for analysis purposes. The clinic BP of the patients who completed the full protocol is shown in Table 3. In the patients receiving enalapril, indomethacin caused a significant rise in supine systolic BP and a trend for a rise in the erect systolic BP. In the patients taking amlodipine, there was no significant difference in the BP between those taking indomethacin or placebo. There were also no significant differences in the supine pulse rate but there was a fall in the erect pulse rate in the patients taking enalapril when they received indomethacin. The ambulatory BP data are presented in Table 4. In the patients receiving enalapril, indomethacin caused a significant rise in the 24-h mean systolic and diastolic BP, the daytime and nighttime BP (Figs. 1, 2). There was a trend for the morning BP to rise, which was not significant for systolic, but was for diastolic BP (Table 4). There was a significant fall in pulse rate in the patients receiving indomethacin while taking enalapril. In the patients taking amlodipine, when they were given indomethacin there were no significant changes in the systolic or diastolic BP or pulse rate during any of the periods analyzed. The change in 24-h mean systolic BP in patients taking amlodipine receiving indomethacin was less than that in those patients taking enalapril receiving indomethacin (Table 4, Fig. 1). In addition to the primary analysis being positive the other analyses reached significance or had a trend for all BP measured. Fall in pulse rate in the patients receiving enalapril was greater than in those taking amlodipine. The mean changes in 24-h BP caused by indomethacin in patients taking enalapril and amlodipine are shown in Fig. 1 and are highly significant. The response of the individuals is indicated in Fig. 3 and the responses to indomethacin in people taking amlodipine are distributed around 0. Most of the patients taking enalapril had a rise in BP with indomethacin and in some patients this rise was quite marked. The weight in both groups of patients increased by

4 1164 MORGAN ET AL AJH NOVEMBER 2000 VOL. 13, NO. 11 TABLE 3. EFFECT OF INDOMETHACIN ON CLINIC BLOOD PRESSURE IN PATIENTS TAKING ENALAPRIL AND AMLODIPINE (n 18) (n 23) Placebo Indomethacin P Placebo Indomethacin P P, v Supine Systolic Diastolic Pulse Erect Systolic Diastolic Pulse Results are given as mean S.D. These data are for the patients who satisfactorily completed the ambulatory blood pressure monitoring on both occasions. The P value in the far left column refers to the comparison of the change in blood pressure in people taking enalapril with the change in those taking amlodipine. approximately 1 kg when they were given indomethacin. The plasma renin fell in both groups, probably indicating sodium retention. Patients taking enalapril had a higher plasma renin than those patients taking amlodipine while taking placebo. There were changes in the aldosterone level that were of marginal significance (Table 5). Side Effects The occurrence of drug-related side effects was similar in each group, with six patients complaining of side effects (Table 6). The most common effects were gastrointestinal, with abdominal pain, indigestion, and nausea being the most common. This caused the drug to be stopped in a number of the patients early in the study and these patients data were not analyzed. The side effects that caused cessation of therapy are indicated in Table 6. DISCUSSION The patients in both arms of the study (enalapril and amlodipine arm) were relatively similar in their demographics and characteristics though it is feasible that the drug had been selected for specific reasons in these patients and thus they were not randomly matched. Indomethacin caused a rise in the ambulatory BP measurements in patients taking enalapril and associated with this rise was a fall in pulse rate, possibly as a consequence of the rise in BP activating the baroreflex. Conversely, in the patients controlled tak- TABLE 4. BLOOD PRESSURE WHILE TAKING PLACEBO AND INDOMETHACIN RECORDED BY AMBULATORY MONITORING IN PATIENTS TAKING ENALAPRIL OR AMLODIPINE (n 18) (n 23) Placebo Indomethacin P Placebo Indomethacin P P, v 24-h mean Systolic Diastolic Pulse Daytime mean Systolic Diastolic Pulse Nighttime mean Systolic Diastolic Pulse Morning mean Systolic Diastolic Pulse

5 AJH NOVEMBER 2000 VOL. 13, NO. 11 INDOMETHACIN AND HYPERTENSION 1165 FIG. 1. The 24-h systolic blood pressure profile in patients on enalapril or amlodipine when given placebo and indomethacin. BP blood pressure. FIG. 2. The effect of indomethacin on 24-h ambulatory blood pressure in hypertensive patients controlled on enalapril or amlodipine. Abbreviation as in Fig. 1. FIG. 3. Distribution of alteration in 24-h mean ambulatory systolic and diastolic blood pressure in patients on enalapril or amlodipine who were given indomethacin. In this figure, all data have been included even if ambulatory blood pressure monitoring over 24 h was not satisfactory. In such cases, the change in blood pressure over the comparable recordings on the two traces have been compared (n 23 enalapril, n 26 amlodipine). Abbreviation as in Fig. 1. ing amlodipine there was no rise in BP and no alteration in pulse rates. The differences between the two groups were significant. This difference was significant not only for the mean 24-h BP but also for the daytime and nighttime means. It was not significant for the morning rise in BP; this possibly relates to the greater variation that occurs in this BP because of the inconsistency of the time of arising and thus inclusion of a wider range of values. Results with clinic BP were not as conclusive and this probably relates to the fewer number of measurements. However, both at Week 2 (not shown) and Week 3 of the study there was a significant rise in BP in patients taking enalapril treated with indomethacin, whereas the change in BP in those patients taking amlodipine treated with indomethacin was not significant. However, the difference between the two groups did not reach significance. In a small previous study, we demonstrated that indomethacin elevated clinic BP in people controlled by taking enalapril but not in those controlled taking felodipine. 11 This study supports that conclusion but extends the observation to demonstrate that there is a significant effect on the various ambulatory BP measurements and demonstrates that well-controlled individuals may go out of control. Similar conclusions were reached comparing the effect of indomethacin on people controlled taking nifedipine GITS and enalapril. 10 A recent study inferred that this effect was not seen when indomethacin was given to people controlled taking an AT 1 receptor blocking drug com-

6 1166 MORGAN ET AL AJH NOVEMBER 2000 VOL. 13, NO. 11 TABLE 5. EFFECT OF INDOMETHACIN ON WEIGHT, RENIN, AND ALDOSTERONE LEVELS Placebo Indomethacin P Placebo Indomethacin P Weight (kg) Renin (ng/ml/h) Aldosterone (pmol/l) Mean SD. pared to placebo. 12 However, there were only eight people in the study and the power to show an effect was small. The mechanism of the rise in BP with indomethacin in both untreated and treated hypertensive patients is unclear. Indomethacin is a nonselective inhibitor of cyclooxygenase. It interferes with the synthesis of prostaglandins and this has an effect on the kidney, causing sodium retention. 2,13,14 It may also possibly have an effect on blood vessels, causing lack of vasodilatation and hence a rise in BP. Our hypothesis is that the most likely cause is explained by the weight gain, which indicates sodium retention. 11 In patients receiving an ACE inhibitor plasma renin is initially high because of inhibition of the short feedback loop caused by angiotensin II. However, in people taking an ACE inhibitor this high plasma renin has minimal effect on BP as there is a block to formation of angiotensin II. In both people taking enalapril and amlodipine there was a fall in plasma renin caused by sodium retention. In a normal person or an untreated person this fall in plasma renin activity and hence angiotensin II level ameliorates the rise in BP caused by sodium retention and volume expansion, in the same way as the response to sodium restriction and diuretics is blunted by the rise in plasma renin. 6 In the patients taking enalapril, even though there is a fall in renin TABLE 6. TREATMENT-RELATED ADVERSE EVENTS AND WITHDRAWALS Placebo Indomethacin Placebo Indomethacin Indigestion 0 1 (1) 0 3 (2)* Abdominal pain (2)* Vomiting 0 1 (1) 0 0 Tachycardia 1 (1) Cough Nausea 0 1 (1) 0 0 Headache No. of patients 1 (1) 5 (3) 0 (0) 6 (3) Number withdrawn in (). *Some patients had one or more symptoms. levels there will be no significant alteration in angiotensin II and thus the rise in BP from sodium retention is unchecked. In patients receiving a calcium-channel blocking drug the fall in plasma renin and the subsequent fall in angiotensin II means that the full effect of sodium retention is not seen as it is compensated for by the fall in renin and thus angiotensin II. In addition, people taking calcium-channel blocking drugs have a relative insensitivity to sodium intake and this may be another explanation. 7,8 Polónia et al 10 had similar results related to weight gain but because the increase in weight was similar in both groups they argued that the mechanism would not be caused by sodium retention but by some other mechanism. They ignored the crucial role that alterations in renin might play though the data in their study related to renin are confusing as the plasma renin in patients taking enalapril is only slightly elevated. Patients who respond to an ACE inhibitor usually also appear to response to a calcium-channel blocking drug but the reverse is not true. 15 This is probably because angiotensin II acts only on the receptor-mediated Ca 2 channel and unless there is angiotensin II present it is unlikely that ACE inhibitors will have a major effect. Calcium-channel blocking drugs, on the other hand, act on the voltage-regulated channel and this will allow a response to occur in many more patients than with the ACE inhibitor drug. From this study we would conclude two major points. First, if a person is taking a NSAID it is likely that they will respond better to a dihydropyridine calcium-channel blocking drug than to an ACE inhibitor. This point was not evaluated explicitly in this study but is a logical conclusion. However, the main point is that if a hypertensive person receives an NSAID intermittently it would be preferable to control them with a calcium-channel blocking drug rather than an ACE inhibitor, as the control is not abrogated during their NSAID medication. ACKNOWLEDGMENTS We acknowledge the cooperation of the patients and the nursing staff at the Hypertension Clinic at the ARMC Heidelberg.

7 AJH NOVEMBER 2000 VOL. 13, NO. 11 INDOMETHACIN AND HYPERTENSION 1167 REFERENCES 1. Brown J, Dollery C, Vades G: Interaction of non-steroidal anti-inflammatory drugs with antihypertensive and diuretic agents: control of vascular reactivity by endogenous prostanoids. Am J Med 1986; 81(suppl 2B): Watkins J, Abbott EC, Hensby CN, Webster J, Dollery CT: Attenuation of the hypotensive effect of propranolol and thiazide diuretics of indomethacin. Br Med J 1980;281: Chalmers JP, West MJ, Wing LMH, Bune AJC, Graham JR: Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens [A] 1984;6: Morgan TO, Anderson A, Wilson D, Murphy J, Nowson C: The effect of perindopril on blood pressure in humans on different sodium intakes. J Cardiovasc Pharmacol 1987;10(suppl 7):S116 S Morgan TO, Creed R, Hopper J: Factors that determine the response of people with mild hypertension to a reduced sodium intake. Clin Exp Hypertens 1986;A8: Anderson A, Morgan TO, Wilson D, Nowson C, Murphy J, Snowden R: Use of sodium restriction and enalapril in persons with moderate to severe hypertension. Med J Aust 1987;146: Morgan TO, Anderson A, Wilson D, Myers J, Murphy J, Nowson C: Paradoxical effect of sodium restriction on blood pressure in people on slow channel calcium blocking drugs. Lancet 1986;1: Morgan TO, Anderson A: Interaction of slow channel calcium blocking drugs with sodium restriction, diuretics and converting enzyme inhibitors. J Hypertens 1988; 6(suppl 4):S652 S Cappuccio FP, Markandu ND, Tucker F, Sagnella GA, MacGregor GA: Does a diuretic cause a further fall in blood pressure in hypertensive patients already on nifedipine? J Hypertens 1987;5: Polónia J, Boaventura I, Gama G, Camões I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueira-Gomes M: Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressurereducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995;13: Anderson A, Morgan TO: Interaction of indomethacin with felodipine and enalapril. J Hypertens 1993; 11(suppl 5):S338 S Olsen ME, Thomsen T, Hassager C, Ibsen H, Dige- Petersen H: Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals. Am J Hypertens 1999;12: Laiwah ACY, Mactier RA: Antagonistic effect of nonsteroidal anti-inflammatory drugs on furosemide-induced diuresis in cardiac failures. Br Med J 1981;283: Ferri C, Bellini C, Piccoli A, Carlomagno A, Bonavita MS, Santucci A, Balsano F: Enhanced blood pressure response to cyclooxygenase inhibition in salt sensitive human essential hypertension. Hypertension 1993;21: Morgan TO, Anderson A: Haemodynamic comparisons of enalapril and felodipine and their combination. Kidney Int 1992;41(suppl 36);S78 S81.

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment

More information

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments

More information

Dr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.

Dr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION. Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;

More information

Hypertension in Systemic Diseases

Hypertension in Systemic Diseases Hypertension in Systemic Diseases Prof. Andrzej Więcek FRCP (Edin.), FERA Department of Nephrology, Transplantation and Internal Medicine Medical University of Silesia, Katowice, Poland Hypertension in

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI

DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI 3. Vasodilators Drugs which dilate blood vessels ( decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:

More information

Should beta blockers remain first-line drugs for hypertension?

Should beta blockers remain first-line drugs for hypertension? 1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,

More information

Hypertension. Penny Mosley MRPharmS

Hypertension. Penny Mosley MRPharmS Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

Amlodipine plus Lisinopril Tablets AMLOPRES-L

Amlodipine plus Lisinopril Tablets AMLOPRES-L Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme

More information

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys

More information

Aspirin has perhaps the broadest spectrum

Aspirin has perhaps the broadest spectrum AJH 1999;12:784 789 Effect of Aspirin on Blood Pressure in Hypertensive Patients Taking Enalapril or Losartan James J. Nawarskas, Raymond R. Townsend, Michael D. Cirigliano, and Sarah A. Spinler The ability

More information

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Antihypertensive drugs SUMMARY Made by: Lama Shatat Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone

More information

Calculation of Trough-to-Peak Ratio in the Research Unit Setting

Calculation of Trough-to-Peak Ratio in the Research Unit Setting A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive

More information

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult

More information

Antihypertensive drugs: I. Thiazide and other diuretics:

Antihypertensive drugs: I. Thiazide and other diuretics: Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

The management of hypertension has become

The management of hypertension has become AJH 1997;10:743 749 Additive Effects of Diltiazem and Lisinopril in the Treatment of Elderly Patients With Mild-to-Moderate Hypertension Paul Chan, Chun-Nan Lin, Brian Tomlinson, Tz-Hsin Lin, and Ying-Shiung

More information

BRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.

BRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials. AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti

More information

The hypertensive effects of the renin-angiotensin

The hypertensive effects of the renin-angiotensin Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point

More information

Felodipine vs hydralazine: a controlled trial as third line therapy

Felodipine vs hydralazine: a controlled trial as third line therapy Br. J. clin. Pharmac. (1986), 21, 621-626 Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension CO-OPERATIVE STUDY GROUP* *Members of the co-operative study group were: Responsible

More information

Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University

More information

Summary of recommendations

Summary of recommendations Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level

More information

...SELECTED ABSTRACTS...

...SELECTED ABSTRACTS... The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.

More information

Available from Deakin Research Online: Reproduced with kind permission of the copyright owner.

Available from Deakin Research Online:   Reproduced with kind permission of the copyright owner. Deakin Research Online Deakin University s institutional research repository DDeakin Research Online Research Online This is the published version (version of record) of: Huggins, Catherine E., Margerison,

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept Continents 1- introduction 2- classification/definition 3- classification/etiology 4-etiology in both categories 5- complications

More information

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018 Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/

More information

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015 Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor

More information

Incidental Findings; Management of patients presenting with high BP. Phil Swales

Incidental Findings; Management of patients presenting with high BP. Phil Swales Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental

More information

ASEBP and ARTA TARP Drugs and Reference Price by Categories

ASEBP and ARTA TARP Drugs and Reference Price by Categories ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole

More information

The incidence of transient myocardial ischemia,

The incidence of transient myocardial ischemia, AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand

More information

5.2 Key priorities for implementation

5.2 Key priorities for implementation 5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR: 0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration

More information

Section 3, Lecture 2

Section 3, Lecture 2 59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009

Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA

More information

Get Healthy Stay Healthy

Get Healthy Stay Healthy Hypertension Management WHAT IS HYPERTENSION (HIGH BLOOD PRESSURE)? Blood pressure is a measure of how hard the blood pushes against the walls of your arteries as it moves through your body. It is normal

More information

Antihypertensives. Diagnostic category

Antihypertensives. Diagnostic category Measurement of blood pressure At first assessment, take both arms then choose the one with the higher reading. Beware of orthostatic hypotension. Measure BP in sitting position, and repeat after patient

More information

Hypertension in Paediatric Haematology/Oncology

Hypertension in Paediatric Haematology/Oncology in Paediatric Haematology/Oncology Overview and aetiology: is a common problem in Paediatric Haematology and Oncology patients. There are a number of causes, some related to the disease itself or the treatment,

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed

More information

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR

More information

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit

More information

combination (97 ± 8 beats min-'; 65 ± 4 beats cardiac output may be balanced by the vasodilatation

combination (97 ± 8 beats min-'; 65 ± 4 beats cardiac output may be balanced by the vasodilatation Br J clin Pharmac 1994; 37: 45-51 An assessment of lacidipine and atenolol in mild to moderate hypertension D. LYONS, G. FOWLER, J. WEBSTER, S. T. HALL' & J. C. PETRIE Clinical Pharmacology Unit, Department

More information

Pain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia

Pain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain

More information

Lowering blood pressure in 2003

Lowering blood pressure in 2003 UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor

More information

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1. RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion

More information

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:

More information

COMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan

COMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL

More information

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension (2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers

More information

The Evolution To Treatment Of Hypertension With Advanced Formulation

The Evolution To Treatment Of Hypertension With Advanced Formulation The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High

More information

Diuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Diuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Diuretic Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Potassium-sparing diuretics The Ion transport pathways across the luminal and basolateral

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU

DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

Adult Blood Pressure Clinician Guide June 2018

Adult Blood Pressure Clinician Guide June 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018

More information

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg

HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between

More information

Hypertension. Most important public health problem in developed countries

Hypertension. Most important public health problem in developed countries Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,

More information

Practolol and bendrofluazide in treatment of hypertension

Practolol and bendrofluazide in treatment of hypertension British Heart Journal, I974, 36, 867-87I. Practolol and bendrofluazide in treatment of hypertension D. B. Galloway, A. G. Beattie, and J. C. Petrie From Department of Therapeutics and Clinical Pharmacology,

More information

Baroreflex sensitivity and the blood pressure response to -blockade

Baroreflex sensitivity and the blood pressure response to -blockade Journal of Human Hypertension (1999) 13, 185 190 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Baroreflex sensitivity and the blood pressure

More information

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston

More information

Byvalson. (nebivolol, valsartan) New Product Slideshow

Byvalson. (nebivolol, valsartan) New Product Slideshow Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

Appendix F: Clinical evidence tables

Appendix F: Clinical evidence tables 378 Appendix F: F.1 Blood pressure variability STUDY 1 P. M. Rothwell, S. C. Howard, E. Dolan, E. O'Brien, J. E. Dobson, B. Dahlof, N. R. Poulter, and P. S. Sever. Effects of beta blockers and calciumchannel

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

PHARMACOLOGICAL PROBLEMS

PHARMACOLOGICAL PROBLEMS PHARMACOLOGICAL PROBLEMS 1. A 69 year old woman suffering from CHF has been treated with.25 mg Digoxin tablet daily for last 3 months. But the heart failure is not controlled adequately. What will be the

More information

Akash Ghai MD, FACC February 27, No Disclosures

Akash Ghai MD, FACC February 27, No Disclosures Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%

More information

Trough to peak ratio: current status and applicability

Trough to peak ratio: current status and applicability Journal of Human Hypertension (1998) 12, 55 59 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 REVIEW ARTICLE Trough to peak ratio: current status and applicability Department of Medicine

More information

The antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide

The antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide The antihypertensive and diuretic effects of amiloride and of its combination with hydrochlorothiazide The hypotensive effect as well as changes in serum electrolytes and uric acid of amiloride (AM) and

More information

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,

More information

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs (2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal

More information

HTN talk_l Davis_ /28/2018

HTN talk_l Davis_ /28/2018 1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias 1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should

More information

Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.

Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris. Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.

More information